Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 11/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.52 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | CLK2 | P49760 | 3/20 | 0.47 |
| ▸ | CLK3 | P49761 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | FHIT | P49789 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215200 | 0.87 | CHEK1 (0.51) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL1984452 | 0.85 | FHIT (0.55) | PIM1PIM2PIM3KMOCLK2 | |
| SCHEMBL2214701 | 0.84 | CHEK1 (0.50) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL2218638 | 0.84 | CHEK1 (0.48) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL1561263 | 0.83 | CHEK1 (0.60) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL473761 | 0.82 | PIM1 (0.61) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL473752 | 0.81 | CHEK1 (0.56) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL12512644 | 0.81 | CHEK1 (0.56) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL11929451 | 0.81 | PIM1 (0.58) | CHEK1ACHEPIM1PIM2PIM3 | |
| SCHEMBL1560543 | 0.81 | CHEK1 (0.56) | CHEK1ACHEPIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | claimed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | claimed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | CHEK1 786/4885ACHE 4362/4885PIM1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.